Growth hormone and insulin signalling after acute GH exposure in patients with controlled acromegaly: impact of surgery versus somatostatin analog treatment

2016 ◽  
Author(s):  
Jakob Dal ◽  
Hoyer Katrine Lundby ◽  
Steen B Pedersen ◽  
Nils Magnusson ◽  
Peter Bjerrring ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Insulin Signalling ◽  
Somatostatin Analog

scholarly journals The acute effect of a physiological bolus of growth hormone (GH) on insulin signalling pathways in striated muscle in healthy volunteers

2009 ◽  
Vol 17 (Suppl 2) ◽  
pp. P3
Author(s):  
Thomas Krusenstjerna-Hafstrøm ◽  
Michael Madsen ◽  
Mikkel Vendelboe ◽  
Niels Jessen ◽  
Louise Møller ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Healthy Volunteers ◽  
Striated Muscle ◽  
Insulin Signalling ◽  
Acute Effect ◽  
Signalling Pathways

Effect of the somatostatin analog D-Trp8, D-Cys14 on glucose, insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics

1980 ◽  
Vol 3 (2) ◽  
pp. 189-192 ◽  
Author(s):  
M. Trovati ◽  
F. Massara ◽  
F. Camanni ◽  
G. M. Molinatti ◽  
R. Lorenzati ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Plasma Levels ◽  
Somatostatin Analog ◽  
Pancreatic Glucagon

Suppression of Growth Hormone and Somatomedin C by Long-Acting Somatostatin Analog SMS 201–995 in Type I Diabetes mellitus

1987 ◽  
Vol 27 (1) ◽  
pp. 7-12 ◽  
Author(s):  
Gerd Plewe ◽  
Gerhard Noelken ◽  
Ulrich Krause ◽  
Juergen Beyer ◽  
Emilio del Pozo
Keyword(s):  
Diabetes Mellitus ◽  
Growth Hormone ◽  
Type I Diabetes ◽  
Somatostatin Analog ◽  
Type I Diabetes Mellitus ◽  
Type I ◽  
Somatomedin C ◽  
Long Acting

Effects of growth hormone receptor antagonism and somatostatin analog administration on quality of life in acromegaly

2020 ◽  
Vol 94 (1) ◽  
pp. 58-65
Author(s):  
Laura E. Dichtel ◽  
Allison Kimball ◽  
Kevin C. J. Yuen ◽  
Whitney Woodmansee ◽  
Melanie S. Haines ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Growth Hormone ◽  
Hormone Receptor ◽  
Growth Hormone Receptor ◽  
Somatostatin Analog ◽  
Receptor Antagonism

scholarly journals Case Report: Persistent Acromegaly – Effective Therapy with Lanreotide and Weekly Pegvisomant Injections

2018 ◽  
Vol 05 (01) ◽  
pp. e9-e12 ◽  
Author(s):  
Thomas Schürmeyer ◽  
Britta Galling
Keyword(s):  
Growth Hormone ◽  
Hormone Secretion ◽  
Growth Hormone Secretion ◽  
Residual Tumor ◽  
Pituitary Surgery ◽  
Effective Therapy ◽  
Somatostatin Analog ◽  
Endocrine Control ◽  
Insulin Growth Factor ◽  
Pre Treatment

Abstract Objective Therapeutic options for persistent acromegaly after surgery include another surgical approach, radiotherapy, medical therapy or a combination of these procedures. We describe a patient with persistent acromegaly despite heavy pre-treatment who was in need of a simplified mode of effective therapy. Methods In a 45-year old patient after transsphenoidal pituitary surgery followed by linear accelerator irradiation of the residual tumor two years later acromegaly could not be controlled by a tolerable dosage of intramuscular octreotide LAR. For professional reasons the patient requested a simplified mode of treatment. Results In order to improve efficacy and treatment convenience, we combined subcutaneous injections of lanreotide up to 120 mg monthly performed by the patient’s spouse and of pegvisomant 80 mg weekly conducted by the patient himself. This therapy was well tolerated and satisfactory endocrine control was achieved. Magnetic resonance imaging did not show any remaining tumor within a year. 5 years following surgery and 3 years following irradiation pegvisomant could be stopped and levels of insulin growth factor 1 and growth hormone remained in the normal range. The interval of lanreotide given subcutaneously by the patient’s spouse could be extended stepwise and somatostatin analog treatment was terminated after 7.5 years when the patient was cured. Conclusions Excessive growth hormone secretion persisting after pituitary surgery and irradiation can be controlled in a convenient way for the patient with acromegaly by combining monthly lanreotide and weekly pegvisomant injections, if monotherapy with a somatostatin analog fails.

Sign in / Sign up

Export Citation Format

Share Document